Results 61 to 70 of about 17,322 (222)

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang   +15 more
wiley   +1 more source

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya

open access: yes, 2020
BACKGROUND: Antiretroviral therapy containing an integrase strand transfer inhibitor plus two Nucleoside Reverse Transcriptase inhibitors has now been recommended for treatment of HIV-1-infected patients.
Lihana Raphael   +4 more
core   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani   +7 more
wiley   +1 more source

Will Integrase Inhibitors be Used as Microbicides?

open access: yes, 2012
Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections including HIV-1. Despite more than two decades of HIV-
Crucitti, G. C.   +5 more
core   +1 more source

HIV-1 Integrase Inhibitors

open access: yesDrugs in R & D, 2007
From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it has taken 15 years to achieve success in human clinical trials. Currently available antiretroviral drugs set high clinical standards in efficacy and long-term safety for upcoming novel HIV/AIDS therapeutic agents.
Raveendra, Dayam   +2 more
openaire   +2 more sources

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

open access: yesHIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning   +16 more
wiley   +1 more source

Beyond the effects of HIV infection and integrase inhibitors-based therapies on oral bacteriome [PDF]

open access: yes, 2023
Oral microbiome is the second largest microbial community in humans after gut. Human immunodeficiency virus (HIV) infection triggers an impairment of the immune system which could favour the growth and the colonization of pathogens in the oral cavity ...
Oteo, José A. [0000-0001-7080-6542]   +19 more
core   +1 more source

Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors

open access: yesScientific Reports
Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these
Mhairi J. McCormack   +11 more
doaj   +1 more source

Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening

open access: yesMolecules, 2019
Currently, an increasing number of drugs are becoming available to clinics for the treatment of HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in ...
Cindy Aknin   +5 more
doaj   +1 more source

Prior PrEP use and discontinuation in individuals newly diagnosed with HIV

open access: yesHIV Medicine, EarlyView.
Abstract Background In settings with high uptake of HIV pre‐exposure prophylaxis (PrEP), an increasing proportion of individuals newly diagnosed with HIV report prior PrEP exposure. Understanding patterns of PrEP use, discontinuation and adherence in such settings is essential to inform future HIV prevention strategies.
Rohan Saini   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy